Rep. Gilbert Ray Cisneros, Jr. Buys Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock

Posted by Stanley Muller on Apr 9th, 2026

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). In a filing disclosed on April 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in Agios Pharmaceuticals stock on March 3rd. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 3/27/2026.
Purchased $1,001 – $15,000 in shares of StandardAero (NYSE:SARO) on 3/27/2026.
Purchased $1,001 – $15,000 in shares of FirstService (NASDAQ:FSV) on 3/27/2026.
Sold $1,001 – $15,000 in shares of Charles Schwab (NYSE:SCHW) on 3/27/2026.
Sold $1,001 – $15,000 in shares of Advanced Energy Industries (NASDAQ:AEIS) on 3/27/2026.
Sold $1,001 – $15,000 in shares of Flex (NASDAQ:FLEX) on 3/27/2026.
Purchased $1,001 – $15,000 in shares of LPL Financial (NASDAQ:LPLA) on 3/27/2026.
Purchased $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 3/27/2026.
Sold $1,001 – $15,000 in shares of Viavi Solutions (NASDAQ:VIAV) on 3/27/2026.
Purchased $15,001 – $50,000 in shares of Fabrinet (NYSE:FN) on 3/27/2026.

Agios Pharmaceuticals Price Performance

Shares of AGIO traded down $0.96 during trading hours on Thursday, hitting $32.82. The company’s stock had a trading volume of 266,200 shares, compared to its average volume of 936,219. The business has a 50 day simple moving average of $29.24 and a two-hundred day simple moving average of $32.11. Agios Pharmaceuticals, Inc. has a 52-week low of $22.24 and a 52-week high of $46.00. The company has a market cap of $1.92 billion, a price-to-earnings ratio of -4.62 and a beta of 0.79.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of AGIO. AQR Capital Management LLC raised its position in shares of Agios Pharmaceuticals by 66.8% in the first quarter. AQR Capital Management LLC now owns 51,489 shares of the biopharmaceutical company’s stock worth $1,498,000 after buying an additional 20,625 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Agios Pharmaceuticals by 7.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,327 shares of the biopharmaceutical company’s stock worth $1,274,000 after acquiring an additional 2,920 shares during the last quarter. NewEdge Advisors LLC purchased a new stake in shares of Agios Pharmaceuticals in the 1st quarter valued at about $40,000. Goldman Sachs Group Inc. raised its holdings in shares of Agios Pharmaceuticals by 16.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 658,652 shares of the biopharmaceutical company’s stock valued at $19,299,000 after acquiring an additional 91,482 shares in the last quarter. Finally, Woodline Partners LP bought a new stake in shares of Agios Pharmaceuticals during the 1st quarter valued at about $597,000.

Insider Activity at Agios Pharmaceuticals

In other news, insider James William Burns sold 3,280 shares of the stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $34.71, for a total value of $113,848.80. Following the transaction, the insider owned 49,306 shares of the company’s stock, valued at $1,711,411.26. This represents a 6.24% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Sarah Gheuens sold 2,940 shares of the firm’s stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $34.71, for a total transaction of $102,047.40. Following the sale, the insider owned 80,277 shares in the company, valued at approximately $2,786,414.67. This trade represents a 3.53% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 15,582 shares of company stock valued at $520,405 in the last ninety days. Insiders own 4.30% of the company’s stock.

Wall Street Analysts Forecast Growth

AGIO has been the topic of a number of analyst reports. Truist Financial boosted their target price on shares of Agios Pharmaceuticals from $32.00 to $38.00 and gave the company a “buy” rating in a report on Wednesday, December 24th. Leerink Partners raised their price target on Agios Pharmaceuticals from $34.00 to $40.00 and gave the stock an “outperform” rating in a report on Friday, December 26th. Bank of America boosted their price objective on Agios Pharmaceuticals from $32.00 to $34.00 and gave the company a “buy” rating in a research note on Wednesday, December 24th. Citigroup increased their price objective on Agios Pharmaceuticals from $38.00 to $46.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Finally, Wall Street Zen upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, March 22nd. Six equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Agios Pharmaceuticals currently has an average rating of “Hold” and an average price target of $42.67.

Get Our Latest Analysis on Agios Pharmaceuticals

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Agios Pharmaceuticals

(Get Free Report)

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.